Clovis Oncology (NASDAQ:CLVS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, BidAskClub r
Shares of Clovis Oncology (NASDAQ:CLVS) have received a consensus rating of “Hold” from the sixteen analysts that are presently covering the company, Marketbeat.com reports. Three analysts have ra
SVB Leerink cut shares of Clovis Oncology (NASDAQ:CLVS) from a market perform rating to an underperform rating in a research report sent to investors on Monday morning, Benzinga reports. The firm curr
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc's Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemothe
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc’s Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to…
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc's Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemothe
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Clovis Oncology (NASDAQ:CLVS) fell 9.5% on Monday . The company traded as low as $8.10 and last traded at $8.17, 6,168,184 shares changed hands during trading. A decline of 15% from the aver
Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.

's Top Upgrades, Downgrades For April 27, 2020

01:32pm, Monday, 27'th Apr 2020
Upgrades For Alliance Data Systems Corp (NYSE: ADS), Compass Point upgraded the stock from Neutral to Buy. Alliance Data Systems earned $0.75 in the first quarter...

Clovis down 3% premarket as Leerink cuts view

10:52am, Monday, 27'th Apr 2020
Clovis Oncology (NASDAQ:CLVS) slips 3% premarket on light volume on the heels of a downgrade to Underperform at SVB Leerink citing positive overall survival data from a Phase 3 clinical trial, PROfo
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE